

Negative Trials and Assay Sensitivity: An Industry Perspective

R. Michael Poole MD FACP
Chief Medical Officer
Link Medicine Corp.
Cambridge, MA

Disclosure

The presenter is an employee and shareholder of Link Medicine Corporation.

Disclaimer

The presenter is Chief Medical Officer at Link Medicine Corporation. The opinions expressed in this presentation are the professional opinions of the presenter and are not attributable to Link Medicine Corporation.

References Cited in This Presentation

- Critical Path Institute. C-Path Online Data Repository, <http://www.c-path.org/CAMDcodr.cfm>. Accessed March 22, 2011
- Fierce Pharma, Top 10 Layoffs of 2010. <http://www.fiercepharma.com/special-reports/top-10-layoffs-2010>. Accessed March 22, 2011
- Kemp AS et al. Schizophrenia Bulletin 36(3):504-509 2010
- Life Science VC Blog. <http://www.lifescivc.com/>. Accessed March 22 2011
- Paul SM, et al. Nature Reviews Drug Discovery, 9:204 ; March 2010
- Tracy H. Neuroinvestment Research CNS Disorders/Therapeutics: 4th Edition. 2010